Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3; 117th Congress)/Title III

SEC. 301. MEDICARE PART D BENEFIT REDESIGN.

 * (a) Benefit Structure Redesign.—Section 1860D–2(b) of the Social Security Act (42 U.S.C. 1395w–102(b)) is amended—


 * (1) in paragraph (2)—


 * (A) in subparagraph (A), in the matter preceding clause (i), by inserting “for a year preceding 2024 and for costs above the annual deductible specified in paragraph (1) and up to the annual out-of-pocket threshold specified in paragraph (4)(B) for 2024 and each subsequent year” after “paragraph (3)”;


 * (B) in subparagraph (C)—


 * (i) in clause (i), in the matter preceding subclause (I), by inserting “for a year preceding 2024, ” after “paragraph (4),”; and


 * (ii) in clause (ii)(III), by striking “and each subsequent year” and inserting “through 2023”; and


 * (C) in subparagraph (D)—


 * (i) in clause (i)—


 * (I) in the matter preceding subclause (I), by inserting “for a year preceding 2024, ” after “paragraph (4),”; and


 * (II) in subclause (I)(bb), by striking “a year after 2018” and inserting “each of years 2018 through 2023”; and


 * (ii) in clause (ii)(V), by striking “2019 and each subsequent year” and inserting “each of years 2019 through 2023”;


 * (2) in paragraph (3)(A)—


 * (A) in the matter preceding clause (i), by inserting “for a year preceding 2024,” after “and (4),”; and


 * (B) in clause (ii), by striking “for a subsequent year” and inserting “for each of years 2007 through 2023”; and


 * (3) in paragraph (4)—


 * (A) in subparagraph (A)—


 * (i) in clause (i)—


 * (I) by redesignating subclauses (I) and (II) as items (aa) and (bb), respectively, and moving the margin of each such redesignated item 2 ems to the right;


 * (II) in the matter preceding item (aa), as redesignated by subclause (I), by striking “is equal to the greater of—” and inserting “is equal to—


 * “(I) for a year preceding 2024, the greater of—”;


 * (III) by striking the period at the end of item (bb), as redesignated by subclause (I), and inserting “; and”; and


 * (IV) by adding at the end the following:


 * “(II) for 2024 and each succeeding year, $0.”; and


 * (ii) in clause (ii), by striking “clause (i)(I)” and inserting “clause (i)(I)(aa)”;


 * (B) in subparagraph (B)—


 * (i) in clause (i)—


 * (I) in subclause (V), by striking “or” at the end;


 * (II) in subclause (VI)—


 * (aa) by striking “for a subsequent year” and inserting “for each of years 2021 through 2023”; and


 * (bb) by striking the period at the end and inserting a semicolon; and


 * (III) by adding at the end the following new subclauses:


 * “(VII) for 2024, is equal to $2,000; or


 * “(VIII) for a subsequent year, is equal to the amount specified in this subparagraph for the previous year, increased by the annual percentage increase described in paragraph (6) for the year involved.”; and


 * (ii) in clause (ii), by striking “clause (i)(II)” and inserting “clause (i)”;


 * (C) in subparagraph (C)(i), by striking “and for amounts” and inserting “and, for a year preceding 2024, for amounts”; and


 * (D) in subparagraph (E), by striking “In applying” and inserting “For each of years 2011 through 2023, in applying”.


 * (b) Decreasing Reinsurance Payment Amount.—Section 1860D–15(b)(1) of the Social Security Act (42 U.S.C. 1395w–115(b)(1)) is amended by inserting after “80 percent” the following: “(or, with respect to a coverage year after 2023, 20 percent)”.


 * (c) Manufacturer Discount Program.—


 * (1) IN GENERAL.—Part D of title XVIII of the Social Security Act (42 U.S.C. 1395w–101 et seq.), as amended by section 202, is further amended by inserting after section 1860D–14B the following new section:

'''“SEC. 1860D–14C. MANUFACTURER DISCOUNT PROGRAM.'''


 * “(a) Establishment.—The Secretary shall establish a manufacturer discount program (in this section referred to as the ‘program’). Under the program, the Secretary shall enter into agreements described in subsection (b) with manufacturers and provide for the performance of the duties described in subsection (c). The Secretary shall establish a model agreement for use under the program by not later than January 1, 2023, in consultation with manufacturers, and allow for comment on such model agreement.


 * “(b) Terms Of Agreement.—


 * “(1) IN GENERAL.—


 * “(A) AGREEMENT.—An agreement under this section shall require the manufacturer to provide applicable beneficiaries access to discounted prices for applicable drugs of the manufacturer that are dispensed on or after January 1, 2024.


 * “(B) PROVISION OF DISCOUNTED PRICES AT THE POINT-OF-SALE.—The discounted prices described in subparagraph (A) shall be provided to the applicable beneficiary at the pharmacy or by the mail order service at the point-of-sale of an applicable drug.


 * “(C) TIMING OF AGREEMENT.—


 * “(i) SPECIAL RULE FOR 2024.—In order for an agreement with a manufacturer to be in effect under this section with respect to the period beginning on January 1, 2024, and ending on December 31, 2024, the manufacturer shall enter into such agreement not later than 30 days after the date of the establishment of a model agreement under subsection (a).


 * “(ii) 2025 AND SUBSEQUENT YEARS.—In order for an agreement with a manufacturer to be in effect under this section with respect to plan year 2025 or a subsequent plan year, the manufacturer shall enter into such agreement (or such agreement shall be renewed under paragraph (4)(A)) not later than January 30 of the preceding year.


 * “(2) PROVISION OF APPROPRIATE DATA.—Each manufacturer with an agreement in effect under this section shall collect and have available appropriate data, as determined by the Secretary, to ensure that it can demonstrate to the Secretary compliance with the requirements under the program.


 * “(3) COMPLIANCE WITH REQUIREMENTS FOR ADMINISTRATION OF PROGRAM.—Each manufacturer with an agreement in effect under this section shall comply with requirements imposed by the Secretary or a third party with a contract under subsection (d)(3), as applicable, for purposes of administering the program, including any determination under subparagraph (A) of subsection (c)(1) or procedures established under such subsection (c)(1).


 * “(4) LENGTH OF AGREEMENT.—


 * “(A) IN GENERAL.—An agreement under this section shall be effective for an initial period of not less than 12 months and shall be automatically renewed for a period of not less than 1 year unless terminated under subparagraph (B).


 * “(B) TERMINATION.—


 * “(i) BY THE SECRETARY.—The Secretary may provide for termination of an agreement under this section for a knowing and willful violation of the requirements of the agreement or other good cause shown. Such termination shall not be effective earlier than 30 days after the date of notice to the manufacturer of such termination. The Secretary shall provide, upon request, a manufacturer with a hearing concerning such a termination, and such hearing shall take place prior to the effective date of the termination with sufficient time for such effective date to be repealed if the Secretary determines appropriate.


 * “(ii) BY A MANUFACTURER.—A manufacturer may terminate an agreement under this section for any reason. Any such termination shall be effective, with respect to a plan year—


 * “(I) if the termination occurs before January 30 of a plan year, as of the day after the end of the plan year; and


 * “(II) if the termination occurs on or after January 30 of a plan year, as of the day after the end of the succeeding plan year.


 * “(iii) EFFECTIVENESS OF TERMINATION.—Any termination under this subparagraph shall not affect discounts for applicable drugs of the manufacturer that are due under the agreement before the effective date of its termination.


 * “(iv) NOTICE TO THIRD PARTY.—The Secretary shall provide notice of such termination to a third party with a contract under subsection (d)(3) within not less than 30 days before the effective date of such termination.


 * “(c) Duties Described.—The duties described in this subsection are the following:


 * “(1) ADMINISTRATION OF PROGRAM.—Administering the program, including—


 * “(A) the determination of the amount of the discounted price of an applicable drug of a manufacturer;


 * “(B) the establishment of procedures under which discounted prices are provided to applicable beneficiaries at pharmacies or by mail order service at the point-of-sale of an applicable drug;


 * “(C) the establishment of procedures to ensure that, not later than the applicable number of calendar days after the dispensing of an applicable drug by a pharmacy or mail order service, the pharmacy or mail order service is reimbursed for an amount equal to the difference between—


 * “(i) the negotiated price of the applicable drug; and


 * “(ii) the discounted price of the applicable drug;


 * “(D) the establishment of procedures to ensure that the discounted price for an applicable drug under this section is applied before any coverage or financial assistance under other health benefit plans or programs that provide coverage or financial assistance for the purchase or provision of prescription drug coverage on behalf of applicable beneficiaries as the Secretary may specify; and


 * “(E) providing a reasonable dispute resolution mechanism to resolve disagreements between manufacturers, applicable beneficiaries, and the third party with a contract under subsection (d)(3).


 * “(2) MONITORING COMPLIANCE.—


 * “(A) IN GENERAL.—The Secretary shall monitor compliance by a manufacturer with the terms of an agreement under this section.


 * “(B) NOTIFICATION.—If a third party with a contract under subsection (d)(3) determines that the manufacturer is not in compliance with such agreement, the third party shall notify the Secretary of such noncompliance for appropriate enforcement under subsection (e).


 * “(3) COLLECTION OF DATA FROM PRESCRIPTION DRUG PLANS AND MA–PD PLANS.—The Secretary may collect appropriate data from prescription drug plans and MA–PD plans in a timeframe that allows for discounted prices to be provided for applicable drugs under this section.


 * “(d) Administration.—


 * “(1) IN GENERAL.—Subject to paragraph (2), the Secretary shall provide for the implementation of this section, including the performance of the duties described in subsection (c).


 * “(2) LIMITATION.—In providing for the implementation of this section, the Secretary shall not receive or distribute any funds of a manufacturer under the program.


 * “(3) CONTRACT WITH THIRD PARTIES.—The Secretary shall enter into a contract with 1 or more third parties to administer the requirements established by the Secretary in order to carry out this section. At a minimum, the contract with a third party under the preceding sentence shall require that the third party—


 * “(A) receive and transmit information between the Secretary, manufacturers, and other individuals or entities the Secretary determines appropriate;


 * “(B) receive, distribute, or facilitate the distribution of funds of manufacturers to appropriate individuals or entities in order to meet the obligations of manufacturers under agreements under this section;


 * “(C) provide adequate and timely information to manufacturers, consistent with the agreement with the manufacturer under this section, as necessary for the manufacturer to fulfill its obligations under this section; and


 * “(D) permit manufacturers to conduct periodic audits, directly or through contracts, of the data and information used by the third party to determine discounts for applicable drugs of the manufacturer under the program.


 * “(4) PERFORMANCE REQUIREMENTS.—The Secretary shall establish performance requirements for a third party with a contract under paragraph (3) and safeguards to protect the independence and integrity of the activities carried out by the third party under the program under this section.


 * “(5) IMPLEMENTATION.—Notwithstanding any other provision of law, the Secretary may implement the program under this section by program instruction or otherwise.


 * “(6) ADMINISTRATION.—Chapter 35 of title 44, United States Code, shall not apply to the program under this section.


 * “(e) Enforcement.—


 * “(1) AUDITS.—Each manufacturer with an agreement in effect under this section shall be subject to periodic audit by the Secretary.


 * “(2) CIVIL MONEY PENALTY.—


 * “(A) IN GENERAL.—The Secretary may impose a civil money penalty on a manufacturer that fails to provide applicable beneficiaries discounts for applicable drugs of the manufacturer in accordance with such agreement for each such failure in an amount the Secretary determines is equal to the sum of—


 * “(i) the amount that the manufacturer would have paid with respect to such discounts under the agreement, which will then be used to pay the discounts which the manufacturer had failed to provide; and


 * “(ii) 25 percent of such amount.


 * “(B) APPLICATION.—The provisions of section 1128A (other than subsections (a) and (b)) shall apply to a civil money penalty under this paragraph in the same manner as such provisions apply to a penalty or proceeding under section 1128A(a).


 * “(f) Clarification Regarding Availability Of Other Covered Part D Drugs.—Nothing in this section shall prevent an applicable beneficiary from purchasing a covered part D drug that is not an applicable drug (including a generic drug or a drug that is not on the formulary of the prescription drug plan or MA–PD plan that the applicable beneficiary is enrolled in).


 * “(g) Definitions.—In this section:


 * “(1) APPLICABLE BENEFICIARY.—The term ‘applicable beneficiary’ means an individual who, on the date of dispensing a covered part D drug—


 * “(A) is enrolled in a prescription drug plan or an MA–PD plan;


 * “(B) is not enrolled in a qualified retiree prescription drug plan; and


 * “(C) has incurred costs, as determined in accordance with section 1860D–2(b)(4)(C), for covered part D drugs in the year that exceed the annual deductible with respect to such individual for such year, as specified in section 1860D–2(b)(1), section 1860D–14(a)(1)(B), or section 1860D–14(a)(2)(B), as applicable.


 * “(2) APPLICABLE DRUG.—The term ‘applicable drug’, with respect to an applicable beneficiary—


 * “(A) means a covered part D drug—


 * “(i) approved under a new drug application under section 505(c) of the Federal Food, Drug, and Cosmetic Act or, in the case of a biologic product, licensed under section 351 of the Public Health Service Act; and


 * “(ii) (I) if the PDP sponsor of the prescription drug plan or the MA organization offering the MA–PD plan uses a formulary, which is on the formulary of the prescription drug plan or MA–PD plan that the applicable beneficiary is enrolled in;


 * “(II) if the PDP sponsor of the prescription drug plan or the MA organization offering the MA–PD plan does not use a formulary, for which benefits are available under the prescription drug plan or MA–PD plan that the applicable beneficiary is enrolled in; or


 * “(III) is provided through an exception or appeal; and


 * “(B) does not include a selected drug (as defined in section 1192(c)) during a price applicability period (as defined in section 1191(b)(2)) with respect to such drug.


 * “(3) APPLICABLE NUMBER OF CALENDAR DAYS.—The term ‘applicable number of calendar days’ means—


 * “(A) with respect to claims for reimbursement submitted electronically, 14 days; and


 * “(B) with respect to claims for reimbursement submitted otherwise, 30 days.


 * “(4) DISCOUNTED PRICE.—


 * “(A) IN GENERAL.—The term ‘discounted price’ means, with respect to an applicable drug of a manufacturer dispensed during a year to an applicable beneficiary—


 * “(i) who has not incurred costs, as determined in accordance with section 1860D–2(b)(4)(C), for covered part D drugs in the year that are equal to or exceed the annual out-of-pocket threshold specified in section 1860D–2(b)(4)(B)(i) for the year, 90 percent of the negotiated price of such drug; and


 * “(ii) who has incurred such costs, as so determined, in the year that are equal to or exceed such threshold for the year, 70 percent of the negotiated price of such drug.


 * “(B) CLARIFICATION.—Nothing in this section shall be construed as affecting the responsibility of an applicable beneficiary for payment of a dispensing fee for an applicable drug.


 * “(C) SPECIAL CASE FOR CERTAIN CLAIMS.—


 * “(i) CLAIMS SPANNING DEDUCTIBLE.—In the case where the entire amount of the negotiated price of an individual claim for an applicable drug with respect to an applicable beneficiary does not fall above the annual deductible specified in section 1860D–2(b)(1) for the year, the manufacturer of the applicable drug shall provide the discounted price under this section on only the portion of the negotiated price of the applicable drug that falls above such annual deductible.


 * “(ii) CLAIMS SPANNING OUT-OF-POCKET THRESHOLD.—In the case where the entire amount of the negotiated price of an individual claim for an applicable drug with respect to an applicable beneficiary does not fall entirely below or entirely above the annual out-of-pocket threshold specified in section 1860D–2(b)(4)(B)(i) for the year, the manufacturer of the applicable drug shall provide the discounted price—


 * “(I) in accordance with subparagraph (A)(i) on the portion of the negotiated price of the applicable drug that falls below such threshold; and


 * “(II) in accordance with subparagraph (A)(ii) on the portion of such price of such drug that falls at or above such threshold.


 * “(5) MANUFACTURER.—The term ‘manufacturer’ means any entity which is engaged in the production, preparation, propagation, compounding, conversion, or processing of prescription drug products, either directly or indirectly by extraction from substances of natural origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis. Such term does not include a wholesale distributor of drugs or a retail pharmacy licensed under State law.


 * “(6) NEGOTIATED PRICE.—The term ‘negotiated price’ has the meaning given such term in section 423.100 of title 42, Code of Federal Regulations (or any successor regulation), except that, with respect to an applicable drug, such negotiated price shall not include any dispensing fee for the applicable drug.


 * “(7) QUALIFIED RETIREE PRESCRIPTION DRUG PLAN.—The term ‘qualified retiree prescription drug plan’ has the meaning given such term in section 1860D–22(a)(2).”.


 * (2) SUNSET OF MEDICARE COVERAGE GAP DISCOUNT PROGRAM.—Section 1860D–14A of the Social Security Act (42 U.S.C. 1395–114a) is amended—


 * (A) in subsection (a), in the first sentence, by striking “The Secretary” and inserting “Subject to subsection (h), the Secretary”; and


 * (B) by adding at the end the following new subsection:


 * “(h) Sunset Of Program.—


 * “(1) IN GENERAL.—The program shall not apply with respect to applicable drugs dispensed on or after January 1, 2024, and, subject to paragraph (2), agreements under this section shall be terminated as of such date.


 * “(2) CONTINUED APPLICATION FOR APPLICABLE DRUGS DISPENSED PRIOR TO SUNSET.—The provisions of this section (including all responsibilities and duties) shall continue to apply after January 1, 2024, with respect to applicable drugs dispensed prior to such date.”.


 * (3) INCLUSION OF ACTUARIAL VALUE OF MANUFACTURER DISCOUNTS IN BIDS.—Section 1860D–11 of the Social Security Act (42 U.S.C. 1395w–111) is amended—


 * (A) in subsection (b)(2)(C)(iii)—


 * (i) by striking “assumptions regarding the reinsurance” and inserting “assumptions regarding—


 * “(I) the reinsurance”; and


 * (ii) by adding at the end the following:


 * “(II) for 2024 and each subsequent year, the manufacturer discounts provided under section 1860D–14C subtracted from the actuarial value to produce such bid; and”; and


 * (B) in subsection (c)(1)(C)—


 * (i) by striking “an actuarial valuation of the reinsurance” and inserting “an actuarial valuation of—


 * “(i) the reinsurance”;


 * (ii) in clause (i), as inserted by clause (i) of this subparagraph, by adding “and” at the end; and


 * (iii) by adding at the end the following:


 * “(ii) for 2024 and each subsequent year, the manufacturer discounts provided under section 1860D–14C;”.


 * (d) Conforming Amendments.—


 * (1) Section 1860D–2 of the Social Security Act (42 U.S.C. 1395w–102) is amended—


 * (A) in subsection (a)(2)(A)(i)(I), by striking “, or an increase in the initial” and inserting “or, for a year preceding 2024, an increase in the initial”;


 * (B) in subsection (c)(1)(C)—


 * (i) in the subparagraph heading, by striking “AT INITIAL COVERAGE LIMIT”; and


 * (ii) by inserting “for a year preceding 2024 or the annual out-of-pocket threshold specified in subsection (b)(4)(B) for the year for 2024 and each subsequent year” after “subsection (b)(3) for the year” each place it appears; and


 * (C) in subsection (d)(1)(A), by striking “or an initial” and inserting “or, for a year preceding 2024, an initial”.


 * (2) Section 1860D–4(a)(4)(B)(i) of the Social Security Act (42 U.S.C. 1395w–104(a)(4)(B)(i)) is amended by striking “the initial” and inserting “for a year preceding 2024, the initial”.


 * (3) Section 1860D–14(a) of the Social Security Act (42 U.S.C. 1395w–114(a)) is amended—


 * (A) in paragraph (1)—


 * (i) in subparagraph (C), by striking “The continuation” and inserting “For a year preceding 2024, the continuation”;


 * (ii) in subparagraph (D)(iii), by striking “1860D–2(b)(4)(A)(i)(I)” and inserting “1860D–2(b)(4)(A)(i)(I)(aa)”; and


 * (iii) in subparagraph (E), by striking “The elimination” and inserting “For a year preceding 2024, the elimination”; and


 * (B) in paragraph (2)—


 * (i) in subparagraph (C), by striking “The continuation” and inserting “For a year preceding 2024, the continuation”; and


 * (ii) in subparagraph (E), by striking “1860D–2(b)(4)(A)(i)(I)” and inserting “1860D–2(b)(4)(A)(i)(I)(aa)”.


 * (4) Section 1860D–21(d)(7) of the Social Security Act (42 U.S.C. 1395w–131(d)(7)) is amended by striking “section 1860D–2(b)(4)(B)(i)” and inserting “section 1860D–2(b)(4)(C)(i)”.


 * (5) Section 1860D–22(a)(2)(A) of the Social Security Act (42 U.S.C. 1395w–132(a)(2)(A)) is amended—


 * (A) by striking “the value of any discount” and inserting the following: “the value of—


 * “(i) for years prior to 2024, any discount”;


 * (B) in clause (i), as inserted by subparagraph (A) of this paragraph, by striking the period at the end and inserting “; and”; and


 * (C) by adding at the end the following new clause:


 * “(ii) for 2024 and each subsequent year, any discount provided pursuant to section 1860D–14C.”.


 * (6) Section 1860D–41(a)(6) of the Social Security Act (42 U.S.C. 1395w–151(a)(6)) is amended—


 * (A) by inserting “for a year before 2024” after “1860D–2(b)(3)”; and


 * (B) by inserting “for such year” before the period.


 * (7) Section 1860D–43 of the Social Security Act (42 U.S.C. 1395w–153) is amended—


 * (A) in subsection (a)—


 * (i) by striking paragraph (1) and inserting the following:


 * “(1) participate in—


 * “(A) for 2011 through 2023, the Medicare coverage gap discount program under section 1860D–14A; and


 * “(B) for 2024 and each subsequent year, the manufacturer discount program under section 1860D–14C;”;


 * (ii) by striking paragraph (2) and inserting the following:


 * “(2) have entered into and have in effect—


 * “(A) for 2011 through 2023, an agreement described in subsection (b) of section 1860D–14A with the Secretary; and


 * “(B) for 2024 and each subsequent year, an agreement described in subsection (b) of section 1860D–14C with the Secretary; and”; and


 * (iii) by striking paragraph (3) and inserting the following:


 * “(3) have entered into and have in effect, under terms and conditions specified by the Secretary—


 * “(A) for 2011 through 2023, a contract with a third party that the Secretary has entered into a contract with under subsection (d)(3) of section 1860D–14A; and


 * “(B) for 2024 and each subsequent year, a contract with a third party that the Secretary has entered into a contract with under subsection (d)(3) of section 1860D–14C.”; and


 * (B) by striking subsection (b) and inserting the following:


 * “(b) Effective Date.—Paragraphs (1)(A), (2)(A), and (3)(A) of subsection (a) shall apply to covered part D drugs dispensed under this part on or after January 1, 2011, and before January 1, 2024, and paragraphs (1)(B), (2)(B), and (3)(B) of such subsection shall apply to covered part D drugs dispensed under this part on or after January 1, 2024.”.


 * (8) Section 1927 of the Social Security Act (42 U.S.C. 1396r–8) is amended—


 * (A) in subsection (c)(1)(C)(i)(VI), by inserting before the period at the end the following: “or under the manufacturer discount program under section 1860D–14C”; and


 * (B) in subsection (k)(1)(B)(i)(V), by inserting before the period at the end the following: “or under section 1860D–14C”.


 * (e) Effective Date.—The amendments made by this section shall apply with respect to plan year 2024 and subsequent plan years.

SEC. 302. ALLOWING CERTAIN ENROLLEES OF PRESCRIPTION DRUG PLANS AND MA–PD PLANS UNDER MEDICARE PROGRAM TO SPREAD OUT COST-SHARING UNDER CERTAIN CIRCUMSTANCES.
Section 1860D–2(b)(2) of the Social Security Act (42 U.S.C. 1395w–102(b)(2)), as amended by section 301, is further amended—


 * (1) in subparagraph (A), by striking “Subject to subparagraphs (C) and (D)” and inserting “Subject to subparagraphs (C), (D), and (E)”; and


 * (2) by adding at the end the following new subparagraph:


 * “(E) ENROLLEE OPTION REGARDING SPREADING COST-SHARING.—The Secretary shall establish by regulation a process under which, with respect to plan year 2024 and subsequent plan years, a prescription drug plan or an MA–PD plan shall, in the case of a part D eligible individual enrolled with such plan for such plan year who is not a subsidy eligible individual (as defined in section 1860D–14(a)(3)) and with respect to whom the plan projects that the dispensing of the first fill of a covered part D drug to such individual will result in the individual incurring costs that are equal to or above the annual out-of-pocket threshold specified in paragraph (4)(B) for such plan year, provide such individual with the option to make the coinsurance payment required under subparagraph (A) (for the portion of such costs that are not above such annual out-of-pocket threshold) in the form of periodic installments over the remainder of such plan year.”.

SEC. 303. ESTABLISHMENT OF PHARMACY QUALITY MEASURES UNDER MEDICARE PART D.
Section 1860D–4(c) of the Social Security Act (42 U.S.C. 1395w–104(c)) is amended—


 * (1) by redesignating the paragraph (6), as added by section 50354 of division E of the Bipartisan Budget Act of 2018 (Public Law 115–123), as paragraph (7); and


 * (2) by adding at the end the following new paragraph:


 * “(8) APPLICATION OF PHARMACY QUALITY MEASURES.—


 * “(A) IN GENERAL.—A PDP sponsor that implements incentive payments to a pharmacy or price concessions paid by a pharmacy based on quality measures shall use measures established or approved by the Secretary under subparagraph (B) with respect to payment for covered part D drugs dispensed by such pharmacy.


 * “(B) STANDARD PHARMACY QUALITY MEASURES.—The Secretary shall establish or approve standard quality measures from a consensus and evidence-based organization for payments described in subparagraph (A). Such measures shall focus on patient health outcomes and be based on proven criteria measuring pharmacy performance.


 * “(C) EFFECTIVE DATE.—The requirement under subparagraph (A) shall take effect for plan years beginning on or after January 1, 2024, or such earlier date specified by the Secretary if the Secretary determines there are sufficient measures established or approved under subparagraph (B) to meet the requirement under subparagraph (A).”.